Estado del programa
Activo, no reclutaFase
Fase 1Inmunoterapia previa permitida
SíEnsayo dirigido por el CRC
SíEtiquetas
MSI-H/ MMRd, MSS/ MMRpComentarios
For NED (no evidence of disease) patients, who had KRAS/NRAS mutated, G12D or G12R, solid tumor, including colorectal cancer.
Enlaces útiles
https://www.nature.com/articles/s41591-023-02760-3| Ubicación | Situación |
|---|---|
| Estados Unidos | |
|
Ciudad de la Esperanza Duarte, California 91010 |
Activo, no recluta |
|
University of California Los Angeles Los Ángeles, California 90095 |
Activo, no recluta |
|
University of Colorado Aurora, Colorado 80045 |
Activo, no recluta |
|
Universidad de Iowa Iowa City, Iowa 52242 |
Activo, no recluta |
|
Hospital General de Massachusetts Boston, Massachusetts 02114 |
Activo, no recluta |
|
Facultad de Medicina de la Universidad de Washington San Luis, Missouri 63110 |
Activo, no recluta |
|
Northwell Health Lake Success, Nueva York 11042 |
Activo, no recluta |
|
Centro Oncológico Memorial Sloan Kettering Nueva York, Nueva York 10065 |
Activo, no recluta |
|
Tennessee Oncology - Centennial Clinic Nashville, Tennessee 37203 |
Activo, no recluta |
|
Centro Oncológico MD Anderson de la Universidad de Texas Houston, Texas 77030 |
Activo, no recluta |
Criterios de inclusión
Criterios de inclusión:
* KRAS/NRAS mutated (G12D or G12R) solid tumor
* Positive for circulating tumor DNA (ctDNA) and/or elevated serum tumor biomarker despite prior standard therapy including surgery and chemotherapy/radiation therapy where applicable
* Screening CT is negative for recurrent disease
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Criterios de exclusión
Criterios de exclusión:
* Presence of tumor mutations where specific therapy is approved, and the patient is able to receive the approved therapy
* Known brain metastases
* Use of immunosuppressive drugs
